Legacy Wealth Asset Management LLC Takes $253,000 Position in Electromed, Inc. (NYSE:ELMD)

Legacy Wealth Asset Management LLC purchased a new stake in Electromed, Inc. (NYSE:ELMD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,550 shares of the company's stock, valued at approximately $253,000. Legacy Wealth Asset Management LLC owned approximately 0.10% of Electromed at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Navellier & Associates Inc. acquired a new stake in shares of Electromed during the third quarter worth approximately $368,000. Marshall Wace LLP acquired a new stake in Electromed during the 2nd quarter valued at $256,000. Walleye Capital LLC bought a new position in Electromed in the 3rd quarter valued at $274,000. Hunter Associates Investment Management LLC boosted its stake in Electromed by 12.3% in the third quarter. Hunter Associates Investment Management LLC now owns 102,450 shares of the company's stock worth $2,199,000 after purchasing an additional 11,250 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in Electromed in the third quarter worth $226,000. 40.82% of the stock is currently owned by institutional investors.

Electromed Price Performance

Shares of ELMD stock traded up $0.13 during trading hours on Friday, reaching $34.00. 79,128 shares of the company were exchanged, compared to its average volume of 76,680. The company has a market cap of $287.64 million, a price-to-earnings ratio of 41.35 and a beta of 0.31. The stock's fifty day moving average is $29.57 and its two-hundred day moving average is $22.27. Electromed, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $34.25.

Electromed (NYSE:ELMD - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.13. The firm had revenue of $14.67 million for the quarter. Electromed had a return on equity of 15.32% and a net margin of 11.34%.

Insider Buying and Selling

In other Electromed news, Director Andrew Summers sold 12,731 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $29.98, for a total transaction of $381,675.38. Following the completion of the sale, the director now owns 165,755 shares in the company, valued at approximately $4,969,334.90. The trade was a 7.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.00% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Electromed from a "strong-buy" rating to a "buy" rating in a report on Thursday, January 9th.

Electromed Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.